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linical trial comparisons of treatments can provide impor-
ant evidence to improve health policy, patient care man-
gement, and clinician and patient informed decisions.
ssuming a clinical trial has been well designed and
uccessfully implemented (i.e., internal validity has been
stablished), its findings may provide important treatment-
elated information to guide future care for the study-
elevant populations.
See pages 490 and 499
A key challenge in reviewing any clinical trial findings is
o evaluate to what degree the published results have
pplicability for general clinical practice. In light of the STICH
Surgical Treatment for Ischemic Heart Failure) trial publica-
ions, therefore, in this editorial we examine the generalizabil-
ty of the STICH trial’s surgical ventricular reconstruction
SVR) hypothesis conclusions more broadly (1).
Two key factors related to the STICH trial that warrant
areful consideration include an assessment of patient selec-
ion and treatment appropriateness (2). To evaluate the
TICH trial’s patient selection, it would have been optimal
o have access to an international registry of all patients with
schemic cardiomyopathy to comprehensively compare the
TICH versus non-STICH patient risk factors, processes
f care, and outcomes. A fundamental concern is that
TICH patients volunteering as trial participants may not
e representative of the broader patient population. Specif-
cally, the STICH trial did not include SVR candidates who
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rocedures, as well as the patients who definitely needed
oth SVR and CABG procedures. Pending population
egistry access, comparisons between participating and non-
articipating centers might be performed, as well as com-
arisons between enrolled patients and screened (but not
nrolled patients) at participating sites. As a template to
valuate study generalizability, these types of direct compar-
sons were performed in the Veterans Administration–
ased PSOCS (Processes, Structures, and Outcomes of
are in Cardiac Surgery) multicenter study (3).
eart Failure Impact
eart failure is a major cause of death and disability
orldwide, which imposes a substantial economic burden
4). The prevalence rate for heart failure has been estimated
t 2% in the U.S. (5) and Europe (6). Prevalence rates up to
3% have been reported for the elderly (7).
Heart failure represents a complex clinical syndrome with
rogression modulated by the presence of coexisting condi-
ions such as coronary disease (4). Over the past 2 decades,
mproved treatments for acute myocardial infarction have
mproved survival. Survivors often have reduced left ventric-
lar (LV) function, with immediate ramifications for func-
ional capacity, as well as future progressive remodeling
hanges occurring in LV chamber size and/or LV geometry.
ecause preliminary data from a case-control study indi-
ated promising improvements in LV function after SVR
8), the STICH trial was designed to evaluate whether
ABG either alone or in combination with SVR might
mprove outcomes in patients with heart failure.
he STICH Trial
he STICH trial had a complex study design whereby
istinct patient subpopulations were enrolled to support the
different hypotheses proposed. In the current publications,
atients with ischemic heart failure were enrolled with
oronary artery disease amenable to CABG, with ejection
ractions 35%, as well as dominant anterior LV dysfunc-
ion amenable to SVR. Exclusion criteria included a recent
yocardial infarction, need for aortic valve replacement,
lanned percutaneous coronary intervention, or coexisting
oncardiac disease with a projected life expectancy 3 years.
During enrollment, the STICH trial relied heavily on the
linical judgment of the study physicians to ensure that the
otential benefits and risks to patients were equivalent.
ecause varying physician thresholds for equipoise in treat-
ent assignments were permitted, there was wide diversity in
he characteristics of the 2,136 STICH patients enrolled across
he 127 participating sites in 26 different countries (9).
Despite the pragmatic approach taken to ensure clinician
quipoise, the study’s enrollment process was reportedly “chal-
enging.” Given the extreme variations reported for enrollment
ates across centers and countries, a healthy skepticism arises
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andomization design. To address this concern, in this issue of
he Journal, Jones et al. (9) have designed an innovative
pproach to classify each individual patient’s risk at random-
zation (RAR) using a multivariate model. On the basis of
AR categorical classifications (low, moderate, and high RAR
roupings), the RAR match rates were compared between
igh-volume versus low-volume enrolling centers and coun-
ries. As anticipated, the high-volume enrolling sites generally
nrolled lower-risk patients. Similarly, the low-volume enroll-
ng sites generally enrolled higher-risk patients. Additionally, a
ountry’s specific population characteristics dominated the
AR level for enrolled patients. However, substantial overlap
f RAR categories was demonstrated. For high-volume versus
ow-volume enrolling sites, 85% of enrolled patients had
imilar predicted RAR classifications. Similarly, 76% of pa-
ients across high- versus low-volume enrolling countries
hared similar RAR risk profiles.
In this issue of the Journal, Zembala et al. (10) extracted
TICH-eligible patient records (the closest match of patients
ith ischemic heart failure meeting STICH inclusion and
xclusion criteria) from the Society of Thoracic Surgeons
STS) National Cardiac Database, identifying 104,135
TICH-eligible STS patients, of whom 1,092 (1%) underwent
ABG with SVR. Applying an RAR multivariate regression
lgorithm, the randomized STICH trial patients were com-
ared with the STS CABG plus SVR patients who were
TICH eligible (for the subgroup not enrolled in the STICH
rial). Again, there was a substantial degree of overlap between
hese risk classifications.
Albeit indirect, this novel RAR approach developed by the
TICH team has provided a partial assurance that for the
ajority of patients enrolled, there appears to be general
oncordance of their providers’ assessments of SVR treatment
ligibility, both within the STICH trial and comparing
TICH patients with STS SVR plus CABG patients. Differ-
nces for unmeasured risk factors may remain, however, as the
ercentage of akinesia or dyskinesia of the anterior wall was
eported for only a subset of patients. If your surgical
ractice’s profile for patients with ischemic heart failure (i.e.,
pplying the STICH inclusion and exclusion criteria) is not
ubstantially different, and your surgical revascularization
reatments are similarly performed (i.e., per STICH proto-
ol requirements), the STICH trial’s findings now warrant
our careful consideration.
uture Directions
iven the diversity of “real-world” clinical practice, larger
ulticenter clinical trials with pragmatic patient selection
riteria and/or flexible treatment protocols are more likely to be
epresentative. In contrast, complicated study designs may be
ess likely to have external validity and more likely to have
mportant challenges with clinical interpretability. Trial find-
ngs are inherently affected by high-volume enrolling physi-
ians and/or sites, which may have a differential propensity to
r
ielect patients or may have different outcomes from other
ower-volume enrolling providers. If large variations in center
nrollment rates exist, trial findings reported should verify
hether a “treatment-by-center” effect exists and, where ap-
ropriate, adjust for these effects accordingly.
Ideally, the variation in STICH patient selection would have
een examined by comparing the enrolled patients with the
creened (but not enrolled) patients directly (11). Future
linical trials should be proactively designed and adequately
unded to capture an expanded trial registry to compare
creened versus enrolled patient risk factors, procedures, and
utcomes. Additionally, a randomization scheme should be
sed to ensure treatment arm balance for participating sur-
eons and within participating centers. Comparisons to na-
ional and/or international study-eligible population registries
hould be proactively planned as part of the original study
rotocol to evaluate the representativeness of the trial patients.
In summary, generalizing these recent STICH trial
ndings to support changing your own clinical practice
hould be considered only after careful review of both the
atients selected and the treatments administered.
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